TICKERNERD
Menu
ERASERASHealthcare · Biotechnology

ERAS Stock Forecast: Erasca, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$18
−0.17% on the day

The 10 Wall Street analysts covering Erasca, Inc. hold a median 12-month price target of $23 — +30.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$6.2B
Ticker Nerd rank
55 / 100
Median analyst target
$23
Analysts covering
10
Revenue$0.0
Operating income−$37.9M
Net income−$183.4M
Free cash flow−$177.4M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.7%
1M
−7.9%
YTD
+373.1%
1Y
+1000.0%
From 52W high
−21.7%
From 52W low
+1130.8%
$1
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ERAS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Erasca, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
91
Momentum
86
Accruals
85
Quality
56
Issuance
50
Revisions
35
Volatility
31
Growth
28
Size
21

Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ERAS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ERAS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Oct 25Jan 26Apr 26Jul 26ERASHigh $30Median $23Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $20Median $23High $30

The green dot is the last close — the median target sits +30.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026B of A SecuritiesMaintainsNeutral$18 → $20
13 Aug 2026GuggenheimMaintainsBuy$20 → $21
12 Aug 2026HC Wainwright & Co.MaintainsBuy$18 → $22
20 July 2026Morgan StanleyMaintainsEqual-Weight$12 → $21
20 July 2026Morgan StanleyMaintainsEqual-Weight—
14 July 2026B of A SecuritiesMaintainsNeutral$16 → $18
14 July 2026B of A SecuritiesMaintainsNeutral—
4 June 2026B of A SecuritiesUpgradeNeutral$9.00 → $16
4 June 2026B of A SecuritiesUpgradeNeutral—
12 May 2026MizuhoMaintainsOutperform—
27 Apr 2026StifelMaintainsBuy—
18 Mar 2026JP MorganMaintainsOverweight—
16 Mar 2026GuggenheimMaintainsBuy—
13 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026Piper SandlerMaintainsOverweight—
6 Mar 2026Clear StreetMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—
16 Jan 2026Piper SandlerMaintainsOverweight—
13 Jan 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ERAS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ERAS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Erasca, Inc. returned +1000.0% against +19.6% for the S&P 500, dividends included.

ERAS vs S&P 500, last 12 monthsTotal return, rebased to 100
05001,0001,500Oct 25Jan 26Apr 26Jul 26ERASS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ERAS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Erasca, Inc. (ERAS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−40.1×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
15.2×

Cheaper than 7% of US stocks

EV / EBITDA
−40.2×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−78.2%

Higher than 16% of US stocks

Return on assets
−21.4%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Erasca, Inc. (ERAS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Erasca, Inc. has a market value of $6.2B and an enterprise value of $5.9B.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$277.0M.

  • Diluted earnings per share, trailing twelve months: $−0.93.

  • Free cash flow in the twelve months to 31 Mar 2026: −$250.9M, after $81K of capital spending.

  • Shares outstanding: 310.8M.

  • Trailing P/E: −40.1×; forward P/E: −29.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Erasca, Inc. employs 103 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

ERAS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ERASErasca, Inc.$6.2B
55
DNTHDianthus Therapeutics, Inc.$6.0B
60
TVTXTravere Therapeutics, Inc.$6.2B
84
MIRMMirum Pharmaceuticals, Inc.$6.3B
69
DFTXDefinium Therapeutics, Inc.$5.8B
40
COGTCogent Biosciences, Inc.$6.3B
35
XENEXenon Pharmaceuticals, Inc.$5.8B
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Erasca, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ERAS news & analysis

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

GlobeNewsWire · 24 Aug 2026positive

Erasca announced that the FDA granted Fast Track Designation for its pan-RAS molecular glue ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma, following encouraging Phase 1 activity across multiple tumor types including KRAS G12X pancreatic cancer.

Why it matters — Fast Track Designation can expedite development and regulatory review of ERAS-0015, which could be a significant step for Erasca's pipeline given the company's singular focus on RAS/MAPK pathway-driven cancers.

ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Newsfile Corp · 18 Aug 2026negative

Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. The investigation aims to determine whether the company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Why it matters — Erasca watchers would care because the investigation raises questions about whether company leadership met its duties to shareholders and whether legal action could follow.

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

GlobeNewsWire · 11 Aug 2026positive

Erasca provided second quarter 2026 business updates and financial results, highlighting updated ERAS-0015 data showing compelling monotherapy efficacy and favorable tolerability in 2L+ KRAS G12X pancreatic cancer, along with advancement of the panitumumab colorectal cancer combination.

Why it matters — An ERAS watcher would care because positive efficacy and tolerability data for ERAS-0015 in pancreatic cancer could signal a potential pipeline advance for a high-need indication.

Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire · 10 Aug 2026negative

Schall Brown & Schwartz LLP, a shareholder rights litigation firm, announced a class action lawsuit against Erasca, Inc. over alleged violations of securities laws. Investors who purchased Erasca securities have been given until August 10, 2026, to contact the firm regarding the opportunity to lead the lawsuit.

Why it matters — Erasca watchers would be concerned because the company is facing a securities fraud class action lawsuit that could affect investor confidence in the stock.

FAQ

Frequently asked questions about ERAS stock

What is the ERAS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Erasca, Inc. have a median 12-month price target of $23, with estimates ranging from $20 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ERAS stock a buy right now?

Of the 10 analysts covering Erasca, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Erasca, Inc. 55 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ERAS?

As at 22 Aug 2026, Erasca, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).

Will ERAS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +30.7% from the last close, and Ticker Nerd's factor model ranks Erasca, Inc. 55 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ERAS stock forecast for 2030?

No analyst covering Erasca, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERAS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $30 over the next 12 months.

How has ERAS stock performed over the past year?

Erasca, Inc. returned +1000.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Erasca, Inc. do?

Erasca, Inc. is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway.

What is the latest news on ERAS?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma". Erasca announced that the FDA granted Fast Track Designation for its pan-RAS molecular glue ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma, following encouraging Phase 1 activity across multiple tumor types including KRAS G12X pancreatic cancer.

Company

About Erasca, Inc.

Erasca, Inc. is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway. Operating today in the biotechnology and oncology drug development industry, the company concentrates on targeted small-molecule and biologic programs for biomarker-selected patient populations, particularly those with RAS- and MAPK-driven solid tumors. Erasca’s current pipeline includes candidates such as naporafenib, a pan-RAF inhibitor in late-stage clinical evaluation for NRAS-mutated melanoma and other RAS/MAPK tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor that together form a combination strategy to inhibit multiple nodes in the pathway. Additional programs target RAS directly and address resistance mechanisms via approaches like pan-RAS and pan-KRAS inhibitors and EGFR-directed agents. Founded in 2018 and headquartered in San Diego, California, Erasca plays a specialized role in the healthcare market as a developer of precision oncology assets rather than commercialized drugs, collaborating with academic centers and partners to advance its clinical trials.

CEO Dr. Jonathan E. Lim M.D. · 103 employees · United States · https://www.erasca.com